Background It had been reported that Jurkat cells treated with serum from ankylosing spondylitis (AS) patients exhibited increased Wnt signaling compared with cells treated with control serum . Whether serum from AS patients also has such effect on osteosarcoma cell line MG63 is unknown. Meloxicam could down-regulate wnt pathway in adenomas . Whether it could inhibit the activation of serum from AS patients to wnt pathway in MG63 has not been discussed about.
Objectives To investigate whether serum from patients with AS could activate Wnt/β-catenin pathway in MG63, and whether meloxicam could inhibit this activation or not.
Methods We collected serum from 45 untreated AS patients and 45 healthy volunteers. And we cultured MG63 with the serum mentioned above for two days. We also added meloxicam to MG63 after it cultured with serum from AS patients for an other day. We used western blot to detect the protein expression of active β-catenin. And we used realtime polymerase chain reaction to detect gene expression of PPARD, FOSL1, MMP7, OPG and RANKL in MG63.
Results Cultured with serum from AS patients, the protein expression of active β-catenin and gene expression of PPARD, FOSL1, MMP7, OPG, RANKL in MG63 were all higher than that cultured with serum from healthy subjects (all p<0.05). While adding meloxicam subsequently, the expression of active β-catenin and PPARD, FOSL1, MMP7, OPG, and RANKL in MG63 dropped significantly (all p<0.05).
Conclusions Serum from AS patients could activate Wnt/β-catenin pathway in MG63 and Meloxicam can inhibit this activation.
Daoussis D, Liossis SN, Solomou EE, et al. Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis. Arthritis Rheum. 2010 Jan;62(1):150-8. doi: 10.1002/art.27231.
Dobbie Z, Muller PY, Heinimann K, et al. Expression of COX-2 and Wnt pathway genes in adenomas of familial adenomatous polyposis patients treated with meloxicam. Anticancer Res. 2002 Jul-Aug;22(4):2215-20.
Disclosure of Interest None Declared